Liver function tests as an indicator of adverse maternal and fetal outcomes in patients with hypertensive disorders of pregnancy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250364Keywords:
Hypertensive disorders of pregnancy, Preeclampsia, Adverse maternal and fetal outcomesAbstract
Background: Hypertensive disorders of pregnancy (HDP) are significant contributors to maternal and fetal morbidity and mortality worldwide, with a prevalence in Southeast Asia ranging from 5-15% of pregnancies. In India, the incidence stands at 6.9%. Early detection and management of HDP are vital for improving outcomes. Liver function tests (LFTs) provide a cost-effective tool for assessing HDP severity and predicting complications. This study aims to evaluate the effectiveness of LFTs as a prognostic tool for adverse maternal and fetal outcomes, analyze altered LFT parameters across different HDP types and associated complications, and determine cutoff values for serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT), and lactate dehydrogenase (LDH) in predicting HDP.
Methods: This prospective study was conducted at a tertiary care referral hospital from January 2023 to January 2024. A total of 186 pregnant women diagnosed with HDP were included, excluding those with pre-existing liver disorders. LFTs were performed, and the results were analyzed using statistical package for the social sciences (SPSS) 20.0.
Results: Gestational hypertension was most common (48.9%), followed by severe preeclampsia (33.9%). Elevated LFTs (SGOT, SGPT, ALP, LDH) were significantly associated with adverse outcomes, with LDH showing high sensitivity (97.6%) and specificity (82.1%) at 150 U/l for maternal complications.
Conclusions: Abnormal LFTs, particularly SGOT, SGPT, and LDH, are key prognostic markers for adverse fetal and maternal outcomes in women with HDP, with LDH having the highest predictive significance. Timely intervention for cases with elevated LFTs can reduce maternal and fetal morbidity and mortality.
Metrics
References
Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? Hypertension. 2001;37(2):232-9. DOI: https://doi.org/10.1161/01.HYP.37.2.232
Mehta B, Kumar V, Chawla S, Sachdeva S, Mahopatra D. Hypertension in pregnancy: a community-based study. Indian J Comm Med. 2015;40(4):273-8. DOI: https://doi.org/10.4103/0970-0218.164403
Prakash J, Pandey LK, Singh AK, Kar B. Hypertension in pregnancy: hospital based study. J Assoc Physicians India. 2006;54:273-8.
Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-60. DOI: https://doi.org/10.1097/AOG.0000000000003891
Magee LA, Helewa M, Moutquin J-M, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. SOGC Clinical Practice Guideline, No. 206, March 2008. J Obstet Gynaecol Can. 2008;30(1):S1-48. DOI: https://doi.org/10.1016/S1701-2163(16)32870-5
Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol. 2009;114(6):1326-31. DOI: https://doi.org/10.1097/AOG.0b013e3181c2bde8
Peralta Pedro ML, Basavilvazo R, Cruz Avalar A, Sanchez Ambroz S, Guzman A, Martinez G. Clinical significance of the laboratory determinations of preeclamptic patients. Gynecologia y Obstetriciade. 2004;72:57-62.
Gyawali M, Khadka RR, Jada S, Haider K. Pregnancy induced hypertension and its associated factors among women attending delivery center. Int J Multidiscip Res. 2024;6(1):1-9. DOI: https://doi.org/10.36948/ijfmr.2024.v06i01.13402
Menzies J, Magee LA, Li J, MacNab YC, Yin R, Stuart H, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol. 2007;110:121-7. DOI: https://doi.org/10.1097/01.AOG.0000266977.26311.f0
Nidya K, Tirankar VR. Prognostic significance of liver function tests and platelet indices in predicting maternal and fetal outcomes in pregnancy induced hypertension cases. MedPulse Int J Gynaecol. 2020;13(3):81-6. DOI: https://doi.org/10.26611/10121332
Kozic JR, Benton SJ, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. DOI: https://doi.org/10.1016/S1701-2163(16)35048-4
Alonso AG. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann Hepatol. 2006;5(3):184-6. DOI: https://doi.org/10.1016/S1665-2681(19)32007-1
Sarmah J. Evaluation of serum aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and uric acid in preeclampsia. IOSR J Dent Med Sci Ver. 2015;3(14):2279-861.
Yadav S, Saxena U, Yadav R, Gupta S. Hypertensive disorders of pregnancy and maternal and foetal outcome: a case controlled study. J Indian Med Assoc. 1997;95(10):548-51.
Ye RW, Li HT, Ma R, Ren AG, Liu JM. Prospective cohort study of pregnancy-induced hypertension and risk of preterm delivery and low birth weight. Chinese J Prev Med. 2010;44(1):70-4.
Gaugler-Senden IP, Huijssoon AG, Visser W, Steegers EA, de Groot CJ. Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks’ gestation: audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):216-21. DOI: https://doi.org/10.1016/j.ejogrb.2005.11.011
von Dadelszen P, Payne B, Li J, Ansermino JM, Pipkin FB, Côté AM, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. The Lancet. 2011;377(9761):219-27. DOI: https://doi.org/10.1016/S0140-6736(10)61351-7
Downloads
Published
How to Cite
Issue
Section
